Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
|Videos|April 12, 2022
What’s next for sacral neuromodulation in OAB patients with Parkinson’s disease?
Author(s)Urology Times staff
“I think the take home message is not to take sacral neuromodulation off the table,” says Sarah Martin, DO.
Advertisement
In this video, Sarah Martin, DO, discusses the take-home message from the recent Neurourology & Urodynamics study, “Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review,” for which she served as first author. Martin is an FPMRS fellow at Glickman Urological & Kidney Institute at Cleveland Clinic.
Advertisement
Related to this article
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to OpenFlo urinary catheter
2
FDA grants fast track designation to VIR-5500 for mCRPC
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
5